| Update 2020: management of non-small cell lung cancer M Alexander, SY Kim, H Cheng Lung 198 (6), 897-907, 2020 | 440 | 2020 |
| A podocentric view of nephrology J Ly, M Alexander, SE Quaggin Current opinion in nephrology and hypertension 13 (3), 299-305, 2004 | 97 | 2004 |
| MADD-2, a homolog of the Opitz syndrome protein MID1, regulates guidance to the midline through UNC-40 in Caenorhabditis elegans M Alexander, G Selman, A Seetharaman, KKM Chan, SA D'Souza, ... Developmental cell 18 (6), 961-972, 2010 | 51 | 2010 |
| An UNC-40 pathway directs postsynaptic membrane extension in Caenorhabditis elegans M Alexander, KKM Chan, AB Byrne, G Selman, T Lee, J Ono, E Wong, ... Oxford University Press for The Company of Biologists Limited 136 (6), 911-922, 2009 | 51 | 2009 |
| FGF negatively regulates muscle membrane extension in Caenorhabditis elegans SJ Dixon, M Alexander, R Fernandes, N Ricker, PJ Roy Oxford University Press for The Company of Biologists Limited 133 (7), 1263-1275, 2006 | 44 | 2006 |
| Leptomeningeal metastases in non-small cell lung cancer: optimal systemic management in NSCLC with and without driver mutations M Alexander, E Lin, H Cheng Current treatment options in oncology 21, 1-15, 2020 | 27 | 2020 |
| Tumor mutation burden in lung cancer: a new predictive biomarker for immunotherapy or too soon to tell? M Alexander, J Galeas, H Cheng Journal of Thoracic Disease 10 (Suppl 33), S3994, 2018 | 26 | 2018 |
| Insulin-like signaling negatively regulates muscle arm extension through DAF-12 in Caenorhabditis elegans SJ Dixon, M Alexander, KKM Chan, PJ Roy Developmental biology 318 (1), 153-161, 2008 | 21 | 2008 |
| Lactate levels with glioblastoma multiforme AS Kahlon, M Alexander, A Kahlon, J Wright Baylor University Medical Center Proceedings 29 (3), 313-314, 2016 | 19 | 2016 |
| An Automated Micropositioning System for Investigating C. Elegans Locomotive Behavior W Wang, Y Sun, SJ Dixon, M Alexander, PJ Roy JALA: Journal of the Association for Laboratory Automation 14 (5), 269-276, 2009 | 17 | 2009 |
| VEGF inhibitors in EGFR-mutated lung cancer: a never-ending story? M Alexander, B Halmos Annals of Translational Medicine 6 (23), 2018 | 15 | 2018 |
| The Caenorhabditis elegans homolog of the Opitz syndrome gene, madd-2/Mid1, regulates anchor cell invasion during vulval development MK Morf, I Rimann, M Alexander, P Roy, A Hajnal Developmental biology 374 (1), 108-114, 2013 | 12 | 2013 |
| Detection of plasma EGFR mutations for personalized treatment of lung cancer patients without pathologic diagnosis Q Deng, Q Fang, H Sun, AP Singh, M Alexander, S Li, H Cheng, S Zhou Cancer medicine 9 (6), 2085-2095, 2020 | 10 | 2020 |
| The evolving use of pembrolizumab in combination treatment approaches for non-small cell lung cancer M Alexander, B Ko, R Lambert, S Gadgeel, B Halmos Expert Review of Respiratory Medicine 14 (2), 137-147, 2020 | 10 | 2020 |
| Efficacy and safety of direct oral factor Xa inhibitors in patients after bariatric surgery M Kushnir, R Gali, M Alexander, HHH Billett Blood 134, 2439, 2019 | 10 | 2019 |
| A micropositioning system with real-time feature extraction capability for quantifying C. elegans locomotive behavior WH Wang, Y Sun, SJ Dixon, M Alexander, PJ Roy 2007 IEEE International Conference on Automation Science and Engineering …, 2007 | 6 | 2007 |
| Subcutaneous versus Intravenous Amivantamab, both in Combination with Lazertinib, in Refractory EGFR-mutated NSCLC: Primary Results from the Phase 3 … NB Leighl, H Akamatsu, SM Lim, Y Cheng, AR Minchom, ME Marmarelis, ... Journal of Clinical Oncology, JCO. 24.01001, 2024 | 2 | 2024 |
| 83TiP A phase II study of mecbotamab vedotin (BA3011), a CAB-AXL-ADC, alone and in combination with nivolumab in adult patients with metastatic NSCLC who had prior disease … G Dy, M Alexander, DR Camidge Journal of Thoracic Oncology 18 (4), S88, 2023 | 2 | 2023 |
| Direct oral Xa inhibitors for the treatment of venous thromboembolism after bariatric surgery M Kushnir, R Gali, M Alexander, HH Billett Blood Advances 7 (2), 224-226, 2023 | 2 | 2023 |
| 77tip a phase I/ii dose escalation and dose expansion study of ozuriftamab vedotin (Ba3021) alone and in combination with nivolumab in patients with advanced solid tumors … M Alexander, A Starodub Journal of Thoracic Oncology 18 (4), S84, 2023 | 1 | 2023 |
